Medicines are changing. In laboratories across AstraZeneca, we aim to target any novel biology we uncover. To do this, we are developing an array of new modalities. These potential new therapies are different from the traditional small molecules and current large molecules which are often aimed at targets on the cell surface or delivered without a specific molecular-targeting strategy. As a result, we need advanced drug delivery systems for targeted and controlled release of our novel molecules in tissues and cells in an attempt to optimise their potential benefits for patients. Our scientists are committed to breaking down the barriers between our most promising new drug candidates and their targets in tissues and cells. They are developing a broad range of nanoparticles* that aim to deliver our new modalities to previously undruggable targets and precisely control their release in formulations that are easy to use and convenient for patients. They are also investigating innovative ways of getting oral formulations of biologic drugs across the intestinal wall – something which has eluded generations of drug designers. Our biologists are advancing understanding of cellular transport mechanisms while our chemists, mathematicians and pharmaceutical scientists are using those insights to optimise the design, properties, analysis, formulation and delivery of our potential new medicines.